Showing 2351-2360 of 4063 results for "".
- Retinopathy Risk Increased in T2DM After Cataract Surgeryhttps://modernod.com/news/retinopathy-risk-increased-in-t2dm-after-cataract-surgery/2477965/People with type 2 diabetes are more likely to develop diabetic retinopathy (DR) after cataract surgery, according a new population-based study, according to a Reuters report. Over six years of follow-up, the adjusted risk of retino
- Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate/2477889/Johnson & Johnson announced that through its Janssen Pharmaceutical Companies division that it has accelerated the initiation of the phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the tri
- Early Data Show Moderna’s COVID-19 Vaccine Generates Immune Responseshttps://modernod.com/news/first-covid-19-vaccine-tested-in-the-us-shows-promise-in-data-from-eight-people/2477791/Moderna reported positive interim data from a phase 1 study of its vaccine candidate against SARS-CoV-2, with results showing that mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants in the low- and mid-dose cohorts, reaching or exceeding levels generally seen
- Novavax Granted Up to $384 Million in New CEPI Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-granted-up-to-384-million-in-new-cepi-funding-for-covid-19-vaccine-candidate/2477747/Novavax announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of the company’s vaccine candidate NVX-CoV2373 against SARS-CoV-2. In Ap
- The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Millionhttps://modernod.com/news/the-allergan-foundation-doubles-its-covid-19-response-donations-to-4-0-million/2477733/Allergan announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation’s total COVID-19 donations to date, r
- Market Scope: COVID-19 Fallout Could Reshape Ophthalmology in Indiahttps://modernod.com/news/market-scope-covid-19-fallout-could-reshape-ophthalmology-in-india/2477647/Market Scope estimates the total ophthalmic market in India in 2020 at $1.3 billion, with an optimistic assumption that the COVID-19 suspension of elective surgeries will last for 2 months or less. The firms forecasts a rapid return to 2019 levels of activity, resulting in an overall 25 percent r
- How to Sanitize N95 Masks for Reuse: NIH Studyhttps://modernod.com/news/how-to-sanitize-n95-masks-for-reuse-nih-study/2477607/Exposing contaminated N95 respirators to vaporized hydrogen peroxide (VHP) or ultraviolet (UV) light appears to eliminate the SARS-CoV-2 virus from the material and preserve the integrity of the masks’ fit for up to three uses, a National Institutes of Health (NIH)
- How Ophthalmologists Are Changing Their Surgical Routineshttps://modernod.com/news/how-ophthalmologists-are-changing-their-surgical-routines/2477492/The global COVID-19 pandemic has closed many ophthalmology practices, while others are changing their operations in a big way. Leading ophthalmologists have shared videos with Eyewire News discussing how the pandemic is impacting their practices and what they’re doing in response. To view part 2,
- Avellino Expands Production of Genetic Test Kits for Coronavirus Detectionhttps://modernod.com/news/avellino-expands-production-of-genetic-test-kits-for-coronavirus-detection/2477415/Avellino announced that it is adding additional production shifts for its newly developed coronavirus diagnostic, the Avellino SARS-CoV-2/COVID-19 test. The AvellinoCoV2 ultra-rapid genetic test is in increasing demand by health systems, public health services, and first-responders because of its
- First Patient Dosed in Study of Moderna’s mRNA Vaccine Against COVID-19https://modernod.com/news/first-patient-dosed-in-study-of-modernas-mrna-vaccine-against-covid-19/2477403/Moderna announced that the first subject has been dosed in a phase 1 study of its experimental mRNA vaccine mRNA-1273 against SARS-CoV-2. The phase 1 trial, which is being conducted by the US National Institutes of Health (NIH) at Kaiser Permanente Washington Health Research Institute in Seattle,